1Pfaller MA;Jones RN;Dogern GV.Bloodstream infections due to Candida species:SENTRY antimicrobial surveillance program in North America and Latin America,1997-1998[J],2000(03).
2Abelson JA;Moore T;Bruckner D.Frequency of fungemia in hospitalized pediatric inpatients over 11 years at a tertiary care institution,2005(01).
3Lin MY;Carmeli Y;Zumsteg J.Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia:a case-case-control study[J],2005(11).
4Magill SS;Shields C;Sears CL.Triazole Cross-Risistance among Candida spp.:case report,occurrence among bloodstream isolates,and implications for antifungal therapy[J],2006(02).
5Abi-Said D;Anaissie E;Uzun O.The epidemiology of hematogenous candidiasis caused by different Candida species[J],1997(06).
6Pfaller MA;Messer SA;Hollis R J.In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6 970 clinical isolates of Candida spp[J],2002(06).
7Godov P;Tiraboschi IN;Severo LC.Species distribution and antifungal susceptibility profile of Candida spp.Bloodstream isolates from Latin American hospitals,2003(03).
8Yang Q;Wang L;Lu DN.Prophylactic vaccination with phage-displayed epitope of C.albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice[J],2005(31).
9Cheng MF;Yang YL;Yao TJ.Risk factors for fatal candidemia caused by Candida albicans and non-albicans Candida species[J],2005(01).
10Yera H;Poulain D;Lefebvre A.Polymicrobial candidaemia revealed by peripheral blood smear and chromogenic medium[J],2004(02).
